Clinical Experience with Generic Rasagiline (Ralago<sup>®</sup>) in Patients with Parkinson’s Disease: An Open-Label, Multicenter, Observational Study

Abstract

Background: Antiparkinsonian pharmacotherapy represents one of the most important expenses related to Parkinson's disease. The application of generic drugs may help to reduce the economic burden of the disease; however, efficacy and safety of these products have been less studied. Objective: To investigate the efficacy and safety of generic rasagiline (Ralago ®) from a clinical perspective. Methods: The Clinical Global Impression of Severity scale was used to rate the most important motor and non-motor symptoms at baseline and 12 weeks after the initiation of Ralago ®. Patients also identified symptoms which were the main sources of their disability and distress in everyday life. Results: A total of 499 patients were enrolled (231 females, mean age: 73.2 ± 9.1 years, mean duration of disease: 3.6 ± 3.7 years). Of them, 486 patients completed the study protocol. Both motor and non-motor symptoms showed improvement during 12-week Ralago ® treatment. Adverse events were rare, and the majority of them were not considered as serious. Conclusions: The generic rasagiline (Ralago ®) is an effective and safe generic product.

Pharmacokinetics and Bioequivalence of Rasagiline Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions: An Open, Randomized, Single-Dose, Double-Cycle, Two-Sequence, Crossover Trial

“…Consequently, PD patients have limited choices in these drugs ( Avila et al, 2019 ). Although antiparkinsonian medications are not considered to be the most expensive pharmacological agents, lifelong treatment and often complex drug regimens impose a high economic burden on both patients and the healthcare system ( Pintér et al, 2019 ). Accordingly, the development and application of generic drugs as substitutes for brand-name drugs is a clear and economical choice.…”

The Bioequivalence of Rasagiline Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions

“…Consequently, PD patients have limited choices of these drugs [6] . Although antiparkinsonian medications are not considered to be the most expensive pharmacological agents, lifelong treatment and often complex drug regimens impose a high economic burden on both patients and the healthcare system [14] . Accordingly, the development and application of generic drugs as substitutes for the branded ones is a clear and economic choice.…”